I-BET787, with the CAS number 2201082-98-4, is a small molecule inhibitor primarily known for its role in targeting the bromodomain and extraterminal (BET) family of proteins. These proteins are involved in the regulation of gene expression and play a significant role in various biological processes, including inflammation and cancer. I-BET787 has been studied for its potential therapeutic applications, particularly in oncology, due to its ability to disrupt the interaction between BET proteins and acetylated lysines on histones, thereby influencing transcriptional regulation. The compound is characterized by its selective inhibition of BET bromodomains, which can lead to the downregulation of oncogenes and other genes associated with disease progression. In terms of physical properties, I-BET787 is typically described as a solid compound with specific solubility and stability characteristics that are relevant for its formulation and delivery in biological systems. Its development has contributed to the understanding of epigenetic regulation and has opened avenues for novel treatment strategies in cancer and other diseases.

I-BET787

2201082-98-4: I-BET787, with the CAS number 2201082-98-4, is a small molecule inhibitor primarily known for its role in targeting the bromodomain and extraterminal (BET) family of proteins. These proteins are involved in the regulation of gene expression and play a significant role in various biological processes, including inflammation and cancer. I-BET787 has been studied for its potential therapeutic applications, particularly in oncology, due to its ability to disrupt the interaction between BET proteins and acetylated lysines on histones, thereby influencing transcriptional regulation. The compound is characterized by its selective inhibition of BET bromodomains, which can lead to the downregulation of oncogenes and other genes associated with disease progression. In terms of physical properties, I-BET787 is typically described as a solid compound with specific solubility and stability characteristics that are relevant for its formulation and delivery in biological systems. Its development has contributed to the understanding of epigenetic regulation and has opened avenues for novel treatment strategies in cancer and other diseases.

I-BET787, an orally active pan-BET bromodomain inhibitor, has demonstrated efficacy in murine inflammation models.

CAS 2201082-98-4

I-BET787

I-BET787

Ref: TM-T88532